Eli Lilly has finalized a deal to acquire Kelonia Therapeutics for up to $7 billion, aiming to bolster its position in the oncology market with innovative in vivo gene therapies. The agreement includes an immediate $3.25 billion payment and potential future milestones based on clinical successes. This acquisition comes as Lilly navigates competitive challenges in its obesity drug marketplace and aims to leverage its robust cancer revenue stream, which totaled $9.4 billion last year.
“it’s a big time breakout in Eli Lilly.”
“FDA approves El Eli Liy's GLP1 weight loss pill... starts shipping Monday via Lily Direct. $25 a month with insurance.”
“$25 a month with insurance. 149 to 349 out of pocket depending on the dose.”
“starts shipping Monday via Lily Direct.”
“Guess what? They're going to be using AI. They're using technology to create their blockbuster treatments and solutions, and that's how come, you know, they're going to take over healthcare and they're going to win. But that's they are an AI company, technology company.”
“BREAKING: Eli Lilly to buy Kelonia Therapeutics in up to $7 billion cancer immunotherapy drug deal, @angelicapeebles reports $LLY”
“Rumour confirmed: Lilly bets up to $7B on Kelonia's off-the-shelf CAR-T for myeloma $LLY”
“イーライ・リリー、血液がん治療薬開発のケロニアを買収 最大1兆円 - 日本経済新聞 $LLY”
“$LLY to buy Kelonia for up to $7B. "It's wild, but I think we're setting up for more it would seem," @MizuhoAmericas' Jared Holz reacts to the latest deal and what it says about Eli Lilly's strategy going forward.”
“$LLY is buying Kelonia for $3.25 billion (!!!) upfront + milestone payments that could increase deal size to $7B.”
“$LLY is expanding its genetic medicine capabilities through the acquisition of Kelonia Therapeutics for up to $7 billion, which includes a $3.25 billion upfront payment.”
“The stock is up 0.16% on the announcement.”
